HEPATOLOGY

HEPATOLOGY

Starting with a core expertise in polarized primary cultures of rat hepatocytes, Fluofarma set up a tool box to support to support drug discovery in hepatology. From cell-based screening up to biomarker studies in liver tissues, we offer quantitative and automated approaches to characterize the effects of drug candidates on liver functions and explore their mechanism of action (MOA).

HEPATOLOGY READOUTS

LDL uptake

HepG2 cell line

PF 3.10

Cholestasis / Bile canaliculi network

Primary hepatocytes - sandwich configuration - hepatic tissue

PF 3.16

Glutathione (GSH), intracellular GSH content

Multiple cellular models

PF 3.28

NEW ! Acetaminophen toxicity model (GSH contents, cytolysis)

Mouse primary hepatocytes

PF 3.41

Steatosis/Lipid, intracellular accumulation: neutral lipids

Multiple cellular models

PF 3.29

Lipid, intracellular accumulation: phospholipids

Multiple cellular models

PF 3.30

Mitochondrial Membrane Potential

Multiple cellular models

PF 3.3

MRP2 expression

Primary hepatocytes - sandwich configuration - hepatic tissue

PF 3.5

Cytolysis

Multiple cellular models

PF 3.4

NQO1 expression

Multiple cellular models

PF 3.24

Heme Oxygenase 1 expression

Multiple cellular models

PF 3.25

NAD(P)H / FAD

Multiple cellular models

PF 3.31

PRIMARY CULTURES OF RAT & HUMAN HEPATOCYTES

 

> in vivo-like features: drug metabolizing-enzymes, polarized phenotype, bile canaliculi networks

> in vitro liver disease models based pharmacological treatment

> Screening format: microplates

>>> High-biological relevance, fast turnaround

LIVE CONTENT IMAGING

> No more hidden drug effects: kinetic quantification of drug effects on hepatocyte viability or bile canaliculi structure over several days.


> Accurate compound profiling: generation of time-dependent EC50 values.

>>> Phenotypic screening & drug profiling

HIGH CONTENT ANALYSIS

> Functional assays: Lipid accumulation, hepatobiliary function, redox state, LDL uptake, NADH/FAD content, intracellular Ca2+, mitochondrial function, ... 

> Cell signaling assays: NQO1, HO1, MRP2, GSH, p53, caspase 3/7 ...

HIGH-CONTENT HISTOLOGY

> Generation of in vivo models of liver pathologies

> High-content analysis of liver tissue microarrays

> Automated and multiplexed biomarker quantification

>>> In vivo proof of drug efficacy / safety / mechanism of action

ADDITIONAL CAPABILITIES